Finerenone (BAY94-8862) vs Placebo: Occurence of All-cause Mortality (Full Analysis Set)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.164 | 0.151 | 0.177 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.174 | 0.161 | 0.188 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0106 | -0.0296 | 0.00835 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.939 | 0.839 | 1.05 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.927 | 0.81 | 1.06 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Finerenone (BAY94-8862) than on Placebo | 94.2 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Finerenone (BAY94-8862) | Participants received finerenone 10 mg, 20 mg or 40 mg once daily. | 491 | 3,003 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Participants received matching placebo once daily. | 522 | 2,998 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Occurence of All-cause Mortality (Full Analysis Set) | ClinicalTrials.gov |
| Description | Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table. | ClinicalTrials.gov |
| Time frame | From randomization until end of study, with an average of 32 months | ClinicalTrials.gov |
| Population | Full analysis set (FAS) | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% | ClinicalTrials.gov |
| NCT number | NCT04435626 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Heart Failure | ClinicalTrials.gov |
| Interventions | Finerenone (BAY94-8862), Placebo | ClinicalTrials.gov |
| Lead sponsor | Bayer | ClinicalTrials.gov |
| Results first posted | 2025-08-26 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04435626?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.